obesity drug news today glp-1 september 29 2025 There's lots going on this month at FDA in the world of weight loss drugs. The agency is taking a hard look at the market. Check out these new #FDA Warning Letters Obesity GLP-1 Market Size to

V., Wu, B., Liu, Y

The glucagon receptor activation drives this effect by promoting hepatic fat oxidation, essentially telling the liver to burn its stored fat reserves

These medications lower blood sugar by enhancing insulin release, reducing glucagon secretion, and slowing the emptying of the stomach

doi: 10.2337/dc13-2761

GLP-1s for Cancer Prevention Because population studies are observational, they cant prove that GLP-1s lower cancer risk

However, a long-term exploratory RCT in 150 people with obesity found that differences in eating disorders psychopathology scores were not maintained at 52 weeks when liraglutide in combination with behavioral therapy was compared with behavioral therapy alone 215